|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Dwyer PJ, Eckhardt SG, Haller DG, Tepper
J, Ahnen D, Hamilton S, Benson AB III, Rothenberg M, Petrelli N,
Lenz HJ, et al: Priorities in colorectal cancer research:
Recommendations from the gastrointestinal scientific leadership
council of the coalition of cancer cooperative groups. J Clin
Oncol. 25:2313–2321. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mody K and Bekaii-Saab T: Clinical trials
and progress in metastatic colon cancer. Surg Oncol Clin N Am.
27:349–365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Montagnani F, Chiriatti A, Turrisi G,
Francini G and Fiorentini G: A systematic review of FOLFOXIRI
chemotherapy for the first-line treatment of metastatic colorectal
cancer: Improved efficacy at the cost of increased toxicity.
Colorectal Dis. 13:846–852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanazawa Y, Yamada T, Fujita I, Kakinuma
D, Matsuno K, Arai H, Shimoda T, Ko K, Kato S, Matsutani T, et al:
In vitro chemosensitivity test for gastric cancer specimens
predicts effectiveness of oxaliplatin and 5-fluorouracil.
Anticancer Res. 37:6401–6405. 2017.PubMed/NCBI
|
|
6
|
Pardini B, Kumar R, Naccarati A, Novotny
J, Prasad RB, Forsti A, Hemminki K, Vodicka P and Lorenzo Bermejo
J: 5-Fluorouracil-based chemotherapy for colorectal cancer and
MTHFR/MTRR genotypes. Br J Clin Pharmacol. 72:162–163. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghoshal K and Jacob ST: An alternative
molecular mechanism of action of 5-fluorouracil, a potent
anticancer drug. Biochem Pharmacol. 53:1569–1575. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Latchman J, Guastella A and Tofthagen C:
5-fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme:
Implications for practice. Clin J Oncol Nurs. 18:581–585. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Papanastasopoulos P and Stebbing J:
Molecular basis of 5-fluorouracil-related toxicity: Lessons from
clinical practice. Anticancer Res. 34:1531–1535. 2014.PubMed/NCBI
|
|
10
|
Wang W, McLeod HL, Cassidy J and
Collie-Duguid ES: Mechanisms of acquired chemoresistance to
5-fluorouracil and tomudex: Thymidylate synthase dependent and
independent networks. Cancer Chemother Pharmacol. 59:839–845. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sigmond J, Backus HH, Wouters D, Temmink
OH, Jansen G and Peters GJ: Induction of resistance to the
multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon
cancer cells is associated with thymidylate synthase
overexpression. Biochem Pharmacol. 66:431–438. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peters GJ, Backus HH, Freemantle S, van
Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J,
Calvert AH, Marsh S, et al: Induction of thymidylate synthase as a
5-fluorouracil resistance mechanism. Biochim Biophys Acta.
1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Etienne MC, Chazal M, Laurent-Puig P,
Magné N, Rosty C, Formento JL, Francoual M, Formento P, Renée N,
Chamorey E, et al: Prognostic value of tumoral thymidylate synthase
and p53 in metastatic colorectal cancer patients receiving
fluorouracil-based chemotherapy: Phenotypic and genotypic analyses.
J Clin Oncol. 20:2832–2843. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rahman L, Voeller D, Rahman M, Lipkowitz
S, Allegra C, Barrett JC, Kaye FJ and Zajac-Kaye M: Thymidylate
synthase as an oncogene: A novel role for an essential DNA
synthesis enzyme. Cancer Cell. 5:341–351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cassinelli G, Zuco V, Gatti L, Lanzi C,
Zaffaroni N, Colombo D and Perego P: Targeting the Akt kinase to
modulate survival, invasiveness and drug resistance of cancer
cells. Curr Med Chem. 20:1923–1945. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Das D, Satapathy SR, Siddharth S, Nayak A
and Kundu CN: NECTIN-4 increased the 5-FU resistance in colon
cancer cells by inducing the PI3K-AKT cascade. Cancer Chemother
Pharmacol. 76:471–479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu J, Zhang S, Wang R, Wu X, Zeng L and Fu
Z: Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by
suppressing the PI3K/AKT signaling pathway. Biosci Rep. 37(pii):
BSR201604472017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Das R, Bhattacharya K, Samanta SK, Pal BC
and Mandal C: Improved chemosensitivity in cervical cancer to
cisplatin: Synergistic activity of mechanism through STAT3
inhibition. Cancer Lett. 351:81–90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li CJ, Chu CY, Huang LH, Wang MH, Sheu LF,
Yeh JI and Hsu HY: Synergistic anticancer activity of triptolide
combined with cisplatin enhances apoptosis in gastric cancer in
vitro and in vivo. Cancer Lett. 319:203–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vinod BS, Antony J, Nair HH,
Puliyappadamba VT, Saikia M, Narayanan SS, Bevin A and Anto RJ:
Mechanistic evaluation of the signaling events regulating
curcumin-mediated chemosensitization of breast cancer cells to
5-fluorouracil. Cell Death Dis. 4:e5052013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee YJ, Lee S, Ho JN, Byun SS, Hong SK,
Lee SE and Lee E: Synergistic antitumor effect of ginsenoside Rg3
and cisplatin in cisplatin-resistant bladder tumor cell line. Oncol
Rep. 32:1803–1808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bi T, Zhu A, Yang X, Qiao H, Tang J, Liu Y
and Lv R: Metformin synergistically enhances antitumor activity of
cisplatin in gallbladder cancer via the PI3K/AKT/ERK pathway.
Cytotechnology. 70:439–448. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li C, Zhao Y, Yang D, Yu Y, Guo H, Zhao Z,
Zhang B and Yin X: Inhibitory effects of kaempferol on the invasion
of human breast carcinoma cells by downregulating the expression
and activity of matrix metalloproteinase-9. Biochem Cell Biol.
93:16–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hung TW, Chen PN, Wu HC, Wu SW, Tsai PY,
Hsieh YS and Chang HR: Kaempferol inhibits the invasion and
migration of renal cancer cells through the downregulation of AKT
and FAK pathways. Int J Med Sci. 14:984–993. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang WW, Tsai SC, Peng SF, Lin MW, Chiang
JH, Chiu YJ, Fushiya S, Tseng MT and Yang JS: Kaempferol induces
autophagy through AMPK and AKT signaling molecules and causes G2/M
arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human
hepatic cancer cells. Int J Oncol. 42:2069–2077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng J, Jin Y, Peng J, Wei L, Cai Q, Yan
Z, Lai Z and Lin J: Hedyotis diffusa willd extract
suppresses colorectal cancer growth through multiple cellular
pathways. Oncol Lett. 14:8197–8205. 2017.PubMed/NCBI
|
|
27
|
Chou TC: Synergy determination issues. J
Virol. 76:10577–10578. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Q, Lai Z, Yan Z, Peng J, Jin Y, Wei L
and Lin J: Hedyotis diffusa Willd inhibits proliferation and
induces apoptosis of 5-FU resistant colorectal cancer cells by
regulating the PI3K/AKT signaling pathway. Mol Med Rep. 17:358–365.
2018.PubMed/NCBI
|
|
30
|
Li Q, Wang X, Shen A, Zhang Y, Chen Y,
Sferra TJ, Lin J and Peng J: Hedyotis diffusa Willd
overcomes 5-fluorouracil resistance in human colorectal cancer
HCT-8/5-FU cells by downregulating the expression of P-glycoprotein
and ATP-binding casette subfamily G member 2. Exp Ther Med.
10:1845–1850. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Diantini A, Subarnas A, Lestari K, Halimah
E, Susilawati Y, Supriyatna, Julaeha E, Achmad TH, Suradji EW,
Yamazaki C, et al: Kaempferol-3-O-rhamnoside isolated from the
leaves of Schima wallichii Korth. inhibits MCF-7 breast cancer cell
proliferation through activation of the caspase cascade pathway.
Oncol Lett. 3:1069–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo H, Rankin GO, Li Z, Depriest L and
Chen YC: Kaempferol induces apoptosis in ovarian cancer cells
through activating p53 in the intrinsic pathway. Food Chem.
128:512–519. 2011. View Article : Google Scholar
|
|
33
|
Jo E, Park SJ, Choi YS, Jeon WK and Kim
BC: Kaempferol suppresses transforming growth factor-β1-induced
epithelial-to-mesenchymal transition and migration of A549 lung
cancer cells by inhibiting Akt1-mediated phosphorylation of Smad3
at threonine-179. Neoplasia. 17:525–537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tu LY, Bai HH, Cai JY and Deng SP: The
mechanism of kaempferol induced apoptosis and inhibited
proliferation in human cervical cancer SiHa cell: From macro to
nano: From macro to nano. Scanning. 38:644–653. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu LY, Lu HF, Chou YC, Shih YL, Bau DT,
Chen JC, Hsu SC and Chung JG: Kaempferol induces DNA damage and
inhibits DNA repair associated protein expressions in human
promyelocytic leukemia HL-60 cells. Am J Chin Med. 43:365–382.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song H, Bao J, Wei Y, Chen Y, Mao X, Li J,
Yang Z and Xue Y: Kaempferol inhibits gastric cancer tumor growth:
An in vitro and in vivo study. Oncol Rep. 33:868–874.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ishida K, Ito C, Ohmori Y, Kume K, Sato
KA, Koizumi Y, Konta A, Iwaya T, Nukatsuka M, Kobunai T, et al:
Inhibition of PI3K suppresses propagation of drug-tolerant cancer
cell subpopulations enriched by 5-fluorouracil. Sci Rep.
7:22622017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim EJ, Kang GJ, Kang JI, Boo HJ, Hyun JW,
Koh YS, Chang WY, Kim YR, Kwon JM, Maeng YH, et al: Over-activation
of AKT signaling leading to 5-Fluorouracil resistance in
SNU-C5/5-FU cells. Oncotarget. 9:19911–19928. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nagaraju GP, Alese OB, Landry J, Diaz R
and El-Rayes BF: HSP90 inhibition downregulates thymidylate
synthase and sensitizes colorectal cancer cell lines to the effect
of 5FU-based chemotherapy. Oncotarget. 5:9980–9991. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Larsen BD and Sørensen CS: The
caspase-activated DNase: Apoptosis and beyond. FEBS J.
284:1160–1170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang B, Liu F, Liu Z, Zhang T and Hua D:
B7-H3 increases thymidylate synthase expression via the PI3k-Akt
pathway. Tumor Biol. 37:9465–9472. 2016. View Article : Google Scholar
|
|
43
|
Milczarek M, Rossowska J, Klopotowska D,
Stachowicz M, Kutner A and Wietrzyk J: Tacalcitol increases the
sensitivity of colorectal cancer cells to 5-fluorouracil by
downregulating the thymidylate synthase. J Steroid Biochem Mol
Biol. 190:139–151. 2019. View Article : Google Scholar : PubMed/NCBI
|
